Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSVITA vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Metabolized into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Metabolized by exonucleases to shorter oligonucleotides.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Target-mediated binding to FGF23; low nonspecific binding to other plasma proteins (typical for m Abs).
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
3.8 L (approximately 0.05 L/kg for a 70 kg adult); indicates limited extravascular distribution (confined mainly to plasma volume).
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
Subcutaneous: ~78% relative to intravenous administration (absolute bioavailability not determined due to lack of IV formulation).
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dose adjustment required in renal impairment. Safety and efficacy not established in severe renal impairment (e GFR <30 m L/min/1.73 m²) or on dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dose adjustment recommended for elderly patients (≥65 years). Use based on weight and clinical response.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
None.
None.
Hypersensitivity reactions including anaphylaxis,Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis,Dental abscesses and infections,Local injection site reactions
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
Concomitant use with phosphate binders or active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol),Severe renal impairment or end-stage renal disease
Hypersensitivity to oblimersen or any component of the formulation
Avoid high-phosphorus foods and beverages (e.g., dairy products, nuts, seeds, whole grains, cola, chocolate, organ meats) while on CRYSVITA, as they may increase serum phosphorus levels and risk of hyperphosphatemia. Dietary phosphate restriction is recommended. No specific food-drug interactions known; however, maintain consistent phosphorus intake between doses.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of burosumab to pregnant monkeys during organogenesis resulted in no teratogenic effects at doses up to 5.9 times the human dose. However, due to the mechanism of action, potential risks include disturbances in phosphate and vitamin D metabolism which may affect fetal skeletal development. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
It is not known whether burosumab is excreted in human milk. As a monoclonal antibody, burosumab is likely to be minimally transferred into breast milk and is expected to undergo proteolytic digestion in the gastrointestinal tract. The M/P ratio is unknown. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for CRYSVITA and any potential adverse effects on the breastfed child.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of burosumab may be altered due to pregnancy-induced physiological changes, including increased plasma volume and altered clearance. Monitor serum phosphorus levels and adjust dosing based on clinical response and tolerability. Consider dose adjustments if significant changes in serum phosphorus or adverse effects occur.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
CRYSVITA (burosumab) is a recombinant human monoclonal Ig G1 antibody to fibroblast growth factor 23 (FGF23), indicated for X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older. Administer subcutaneously every 2 weeks (pediatric: starting 0.8 mg/kg, max 1.2 mg/kg; adult: 1.0 mg/kg, max 90 mg). Monitor serum phosphorus closely, aiming for age-appropriate normal range. Do not initiate if serum phosphorus is within normal range. Concomitant use with oral phosphate and active vitamin D analogs is not recommended. May cause injection site reactions, headache, and hyperphosphatemia. Discontinue if severe hypersensitivity occurs. Pregnancy and breastfeeding: limited data; use only if clearly needed.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
CRYSVITA is given as an injection under the skin every 2 weeks. Do not miss doses.,Do not take phosphate supplements or active vitamin D (e.g., calcitriol) while on CRYSVITA unless specifically instructed by your doctor.,Report symptoms of high phosphorus levels: muscle cramps, numbness, tingling, or irregular heartbeat.,Common side effects include injection site reactions (redness, pain, swelling), headache, and back pain.,Pregnancy and breastfeeding: inform your doctor if you are pregnant, plan to become pregnant, or are nursing.,Store CRYSVITA in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Allow to reach room temperature before injecting.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSVITA vs ANTHIM, answered by our medical review team.
CRYSVITA is a Monoclonal Antibody that works by Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSVITA and ANTHIM depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSVITA is: 1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSVITA and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSVITA is classified as Category C. CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal stud. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.